250 related articles for article (PubMed ID: 19037522)
1. Polymyxins: a review of the current status including recent developments.
Kwa AL; Tam VH; Falagas ME
Ann Acad Med Singap; 2008 Oct; 37(10):870-83. PubMed ID: 19037522
[TBL] [Abstract][Full Text] [Related]
2. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
Brown P; Dawson MJ
J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
Paterson DL; Bonomo RA
Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
[TBL] [Abstract][Full Text] [Related]
4. Resistance to polymyxins: Mechanisms, frequency and treatment options.
Falagas ME; Rafailidis PI; Matthaiou DK
Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
[TBL] [Abstract][Full Text] [Related]
5. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
6. [Aminoglycosides and polymyxins].
Molina J; Cordero E; Palomino J; Pachón J
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):178-88. PubMed ID: 19303668
[TBL] [Abstract][Full Text] [Related]
7. Emergence of polymyxin resistance in Gram-negative bacteria.
Olaitan AO; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):581-582. PubMed ID: 27939183
[No Abstract] [Full Text] [Related]
8. Polymyxin antibiotics for gram-negative infections.
Arnold TM; Forrest GN; Messmer KJ
Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
[TBL] [Abstract][Full Text] [Related]
9. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.
Poirel L; Jayol A; Nordmann P
Clin Microbiol Rev; 2017 Apr; 30(2):557-596. PubMed ID: 28275006
[TBL] [Abstract][Full Text] [Related]
10. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
11. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
[TBL] [Abstract][Full Text] [Related]
12. Is it time to move away from polymyxins?: evidence and alternatives.
Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
[TBL] [Abstract][Full Text] [Related]
13. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance--running out of treatment options.
Ruef C
Infection; 2007 Feb; 35(1):1. PubMed ID: 17297581
[No Abstract] [Full Text] [Related]
16. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
17. Polymyxins and their novel derivatives.
Vaara M
Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
[TBL] [Abstract][Full Text] [Related]
18. Colistin, mechanisms and prevalence of resistance.
Bialvaei AZ; Samadi Kafil H
Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
[TBL] [Abstract][Full Text] [Related]
19. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
Almangour TA; Garcia E; Zhou Q; Forrest A; Kaye KS; Li J; Velkov T; Rao GG
Int J Antimicrob Agents; 2021 Jun; 57(6):106328. PubMed ID: 33785362
[TBL] [Abstract][Full Text] [Related]
20. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
Falagas ME; Kasiakou SK
Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
